The Journal of Experimental Medicine
Avanti Polar Lipids, Inc.
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

This Article
Right arrow Full Text
Right arrow Full Text (PDF, 177K)
Right arrow PPT slides of all figures
Right arrow Alert me when this article is cited
Right arrow Citation Map
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new content in the JEM
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sivori, S.
Right arrow Articles by Moretta, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sivori, S.
Right arrow Articles by Moretta, A.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?
© The Rockefeller University Press, 0022-1007/1997/10/1129/ $5.00
The Journal of Experimental Medicine, Volume 186, Number 7, October 6, 1997 1129-1136


Articles

p46, a Novel Natural Killer Cell–specific Surface Molecule That Mediates Cell Activation

Simona Sivori*, Massimo Vitale{ddagger}, Luigia Morelli*, Lorenza Sanseverino*, Raffaella Augugliaro{ddagger}, Cristina Bottino{ddagger}, Lorenzo Moretta{ddagger},§, and Alessandro Moretta*,||

From the * Istituto di Istologia ed Embriologia Generale, Università di Genova, Genova, Italy; {ddagger} Istituto Scientifico Tumori e Centro Biotecnologie Avanzate, Genova, Italy; § Istituto di Patologia Generale, Università di Genova, Genova, Italy; and || Dipartimento di Scienze Biomediche e Biotecnologie, Università di Brescia, Brescia, Italy

Limited information is available on the surface molecules that are involved in natural killer (NK) cell triggering. In this study, we selected the BAB281 monoclonal antibody (mAb) on the basis of its ability to trigger NK-mediated target cell lysis. BAB281 identified a novel NK cell–specific surface molecule of 46 kD (p46) that is expressed by all resting or activated NK cells. Importantly, unlike the NK cell antigens identified so far, the expression of p46 was strictly confined to NK cells. Upon mAb-mediated cross-linking, p46 molecules induced strong cell triggering leading to [Ca2+]i increases, lymphokine production, and cytolytic activity both in resting NK cells and NK cell clones. The p46-mediated induction of Ca2+ increases or triggering of cytolytic activity was downregulated by the simultaneous engagement of inhibitory receptors including p58, p70, and CD94/NKG2A. Both the unique cellular distribution and functional capability of p46 molecules suggest a possible role in the mechanisms of non-major histocompatibility complex–restricted cytolysis mediated by human NK cells.


Address correspondence to Dr. Alessandro Moretta, Istituto di Istologia ed Embriologia Generale, Università di Genova, Via G.B. Marsano 10, 16132 Genova, Italy. Phone: 39-10-353-7862; FAX: 39-10-353-7576.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:



  Home | Help | Feedback | Subscriptions | Archive | Search
TABLE OF CONTENTS